Migraine Headache Clinical Trial
— TENACITYOfficial title:
TENACITY: TelemEdiciNe-bAsed Cognitive Therapy for Migraine
Verified date | August 2023 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this pilot study is to evaluate a bundle of implementation strategies at three Veteran Affairs Medical Centers (VAMCs) to facilitate the referral and adoption of a telehealth based, cognitive behavioral therapy program delivered by Health Psychologists for Veterans with chronic migraine to inform a future fully-powered hybrid type 2 effectiveness-implementation design. Veteran patients will be randomized to either the telehealth delivered CBT or usual care. Headache symptoms and severity will be reported using a VA text messaging application.
Status | Completed |
Enrollment | 80 |
Est. completion date | June 30, 2023 |
Est. primary completion date | May 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Veteran patients eligible to participate must have: - A chronic migraine headache ICD-10 diagnosis; - Completion of at least 28 headache diary days; - A confirmed frequency of at least 8 headache days per month; - A primary complaint of headache Exclusion Criteria: Veteran patients not eligible to participate include: - Non-Veterans; - Veteran patients without a CM headache ICD-10 diagnosis; - Veteran patients whose primary pain complaint is not headache; - Veteran patients who have received greater than or equal to 90 days of opioid therapy for chronic low back pain from the date of chart screening; - Veteran patients who do not speak English; - Veteran patients who have a current diagnosis of severe cognitive impairment indicated by clinical provider, medical chart, or Short Portable Mental Status Questionnaire (SPMSQ); - Veteran patients who have Post Traumatic headache; - Veteran patients who have a diagnosis of cluster headache, other primary headache, post-whiplash headache, secondary headache, or trigeminal autonomic cephalalgia. - Any patients currently suffering from a disabling psychiatric illness (as noted by clinician); - Veteran patients who self-report Traumatic Brain Injury less than or equal to 1 year before diagnosis of Chronic Migraine, or worsening of Chronic Migraine. - Veteran patients who relate daily suicidal ideation within the last 2 weeks as indicated by the PHQ-9 with an answer of "3" to question nine; - Veteran patients who have severe depression, as indicated by PHQ-9 score greater than or equal to 20; - Veteran patients who are deemed by clinicians who are unable to participate in this trial; - Patients who are terminally ill (life expectancy of <12 months as noted by clinician); - Patients who are homeless or live in long-term care, nursing home, rehabilitation, or domiciliary services, etc. - Veteran patients who decline to or cannot use the Annie App; - Veteran patients who decline to or cannot use My HealtheVet secure messaging - Veteran patients who have been treated by a HCoE clinical health psychologist in the last two years |
Country | Name | City | State |
---|---|---|---|
United States | Birmingham VA Medical Center, Birmingham, AL | Birmingham | Alabama |
United States | VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX | Dallas | Texas |
United States | Richard L. Roudebush VA Medical Center, Indianapolis, IN | Indianapolis | Indiana |
United States | VA Connecticut Healthcare System West Haven Campus, West Haven, CT | West Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Goldman RE, Damush TM, Kuruvilla DE, Lindsey H, Baird S, Riley S, Burrone Bs L, Grinberg AS, Seng EK, Fenton BT, Sico JJ. Essential components of care in a multidisciplinary headache center: Perspectives from headache neurology specialists. Headache. 2022 — View Citation
Seng EK, Fenton BT, Wang K, Lipton RB, Ney J, Damush T, Grinberg AS, Skanderson M, Sico JJ. Frequency, Demographics, Comorbidities, and Health Care Utilization by Veterans With Migraine: A VA Nationwide Cohort Study. Neurology. 2022 Sep 13;99(18):e1979-92 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Migraine-Specific Quality of Life Questionnaire (MSQ) | Self-reported migraine related functioning | 3 and 6 months | |
Other | Migraine Disability Assessment (MIDAS) | Self-reported disability due to migraines | 3 and 6 months | |
Other | Headache-specific Pain Catastrophizing Scale (HPCS) | Self-reported headache pain | 3 and 6 months | |
Other | Headache Management Self-Efficacy Scale (HMSE) | Self-reported confidence to manage headaches | 3 and 6 months | |
Other | Personal Health Inventory short form | Self-reported health | 3 and 6 months | |
Other | PCL-5 (PTSD Checklist for DSM-5) | Self-reported PTSD symptoms | 3 and 6 months | |
Other | Patient Health Questionnaire - PHQ-9 | Self-reported depressive symptoms | 3 and 6 months | |
Other | Generalized Anxiety Disorder (GAD-7) | Self-reported anxiety symptoms | 3 and 6 months | |
Other | Veterans RAND 12 (VR-12) | Self-reported functioning and well-being | 3 and 6 months | |
Other | Insomnia Severity Index (ISI) | Self-reported sleep disruptions | 3 and 6 months | |
Primary | Number of Headache Days in the 30 days Prior to 3-Month Mark | Daily self-reported migraine headaches using a VA text message protocol | 30 days prior to 3-Month Outcomes after Baseline | |
Secondary | Implementation fidelity to the core functions of TENACITY | Degree to which the core components of TENACITY are delivered as intended | 3 months | |
Secondary | Budget Impact Analysis | Costs associated with program implementation | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Not yet recruiting |
NCT05943457 -
Vitamin K2 Supplementation in Adult Episodic Migraine
|
N/A | |
Completed |
NCT01211145 -
Zomig - Treatment of Acute Migraine Headache in Adolescents
|
Phase 4 | |
Completed |
NCT00530517 -
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
|
Phase 2 | |
Completed |
NCT00898677 -
Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
|
Phase 3 | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Completed |
NCT03971071 -
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
|
Phase 4 | |
Withdrawn |
NCT02706015 -
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
|
Phase 3 | |
Terminated |
NCT02375789 -
Intranasal Cooling for Symptomatic Relief of Migraine
|
N/A | |
Completed |
NCT02518464 -
Ticagrelor Therapy for RefrACTORy Migraine Study
|
Phase 4 | |
Terminated |
NCT00391755 -
A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches
|
Phase 4 | |
Completed |
NCT03401346 -
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
|
Phase 1 | |
Completed |
NCT05085483 -
Ketone for Migraine Prevention
|
N/A | |
Completed |
NCT01604785 -
Low-dose Propofol for Pediatric Migraine
|
Phase 2/Phase 3 | |
Terminated |
NCT00804973 -
Study in Participants With Acute Migraines Headaches
|
Phase 2 | |
Completed |
NCT03341689 -
Psilocybin for the Treatment of Migraine Headache
|
Phase 1 | |
Completed |
NCT01630044 -
Neurostimulation Device for Treatment of Migraine Headache
|
N/A | |
Active, not recruiting |
NCT00285402 -
Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
|
Phase 2 | |
Completed |
NCT00203255 -
Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache
|
N/A | |
Recruiting |
NCT06046508 -
Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)
|